Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

1. Gianni, L.
2. Lladó, A.
3. Bianchi, G.
4. Cortes, J.
5. Kellokumpu-Lehtinen, P.-L.
6. Cameron, D.A.
7. Miles, D.
8. Salvagni, S.
9. Wardley, A.
10. Goeminne, J.-C.
11. Hersberger, V.
12. Baselga, J.